Advertisement

Topics

"Intravitreal Ranibizumab for VH Due to PDR (N)" Drugs and Medication Database

22:08 EST 23rd February 2019 | BioPortfolio

Here are the most relevant "Intravitreal Ranibizumab for VH Due to PDR (N)" Drugs and Medications that we have found in our database.

More Information about "Intravitreal Ranibizumab for VH Due to PDR (N)" on BioPortfolio

We have published hundreds of Intravitreal Ranibizumab for VH Due to PDR (N) news stories on BioPortfolio along with dozens of Intravitreal Ranibizumab for VH Due to PDR (N) Clinical Trials and PubMed Articles about Intravitreal Ranibizumab for VH Due to PDR (N) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intravitreal Ranibizumab for VH Due to PDR (N) Companies in our database. You can also find out about relevant Intravitreal Ranibizumab for VH Due to PDR (N) Drugs and Medications on this site too.

Showing "Intravitreal Ranibizumab" Drugs and Medications, all 9

Relevant

Eylea [regeneron pharmaceuticals, inc.]

These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA (aflibercept) Injection, for Intravitreal InjectionInitial U.S. Approval: 2011

Probably Relevant

Lucentis [genentech, inc.]

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS. LUCENTIS (ranibizumab injection) for intravitreal injection Initial U.S. Approval: 2006

Macugen [bausch & lomb incorporated]

These highlights do not include all the information needed to use MACUGEN safely and effectively. See full prescribing information for MACUGEN. MACUGEN(pegaptanib sodium injection)Intravitreal InjectionInitial U.S. Approval: 2004

Jetrea [thrombogenics inc.]

These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection, for intravitreal injectionInitial U.S. Approval: 2012

Possibly Relevant

Yutiq [eyepoint pharmaceuticals us, inc]

These highlights do not include all the information needed to use YUTIQ safely and effectively. See full prescribing information for YUTIQ.YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injectionInitial U.S. Approval: 1963

Iluvien [alimera sciences, inc.]

These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg For Intravitreal Injection Initial U.S. Appro

Ozurdex [allergan, inc.]

These highlights do not include all the information needed to use OZURDEX® safely and effectively. See full prescribing information for OZURDEX . OZURDEX (dexamethasone intravitreal implant) For Intravitreal Injection Initial U.S. Approval: 1958

Retisert [bausch & lomb incorporated]

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use Initial U.S. Approval: 19

Firvanq [cutispharma, inc.]

These highlights do not include all the information needed to use FIRVANQ™ safely and effectively. See full prescribing information for FIRVANQ . FIRVANQ (vancomycin hydrochloride) , for oral solution Initial U.S. Approval: 196 4



Advertisement
Quick Search
Advertisement
Advertisement